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Background. S. maltophilia is an important nosocomial pathogen, mainly in immunocompromised patients, and is associated with high mortality. However, data regarding clinical features and risk factors for mortality of S. maltophilia bacteremia in patients with hematologic malignancies are limited.
Methods. We conducted a retrospective analysis of S. maltophilia bacteremia in patients with hematologic malignancies who were treated at Samsung Medical Center, in South Korea, from 2000 to 2012.
Results. During a 13 year period, we identified 101 adult patients with S. maltophilia bacteremia. The median age of the patients was 57 years (IQR, 45-64 years), 87 cases (86.1%) were hospital-acquired, and 25 cases (24.8%) had polymicrobial bacteremia.The most common underlying hematologic malignancy was acute myeloid leukemia (61 [60.4%] of 101) and twenty patients (19.8%) underwent stem cell transplantation. 83.2% of the patients had profound neutropenia and the median duration of neutropenia before the onset of bacteremia onset was 16 days (IQR, 10-26 days). 81 patients (80.2%) received prior antibiotic therapy during the previous month with carbapenem and, in 73 patients (72.3%), breakthrough bacteremia developed during carbapenem treatment. Catheter related infection (59.4%) and pneumonia (30.7%) were the most frequent primary sources of bacteremia. The 14-day mortality rate was 40.6% (41 of 101) and 65 patients (64.4%) received appropriate definitive antimicrobial therapy. Multivariate analysis demonstrated that the independent risk factors for 14-day mortality were pneumonia (OR, 18.76; 95% CI, 3.29-107.06; P = 0.001), septic shock (OR, 15.84; 95% CI, 2.25-111.55; P = 0.006), while appropriate definitive antimicrobial therapy was found to be a protective factor for 14-day mortality (OR, 0.06; 95% CI, 0.01-0.40; P = 0.004).
Conclusion. Physicians should consider S. maltophilia as the causative organism in hematologic malignancy patients, particularly those with the presence of prolonged neutropenia and carbapenem exposure. Although mortality rates were high, appropriate antibiotic therapy may improve the outcome of S. maltophilia bacteremia in patients with hematologic malignancies.
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